ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Sg2 Forecasts Continued Hospital Capacity Challenges as Patient Acuity Rises Over the Next Decade

Sg2, a Vizient company, released its 2023 Impact of Change Forecast, projecting hospital capacity challenges will continue into the next decade, driven by higher patient acuity and staffing shortages. In addition, pharmaceutical and technological advancements will continue to push care delivery, including bariatric surgery, to outpatient status and sites throughout the next decade. Access Sg2 2023 Impact of Change Forecast.

Case mix index, a measure reflecting the diversity, complexity, and severity of patient illnesses, is up 5% since 2019, the year before the pandemic. At the same time average length of stay for patients admitted to a hospital has risen 10%, driven by the increasingly complex nature of the patient population further exacerbating workforce challenges and the closure of 30,000 patient beds between 2019 and 2022. The Forecast projects continued rises in patient acuity, which will strain capacity across sites of care.

“As the population continues to age and chronic disease incidence rises, we expect increased demand across all sites of care. The reality is access is a challenge for these patient populations and care redesign will be critical to prevent the acute exacerbation of their medical conditions,” said Tori Richie, intelligence senior director, Sg2.

Provider organizations also face mounting pressure to redesign care delivery models as pharmaceutical and technological advancements impact procedure types and locations. For example, the report projects nearly 12,000 fewer bariatric surgeries by 2033, a 4% decline, driven by anti-obesity pharmaceuticals entering the market.

Other notable findings in the Forecast include:

  • Emerging service lines for infusion therapy: In addition to bariatric surgery, pharmaceuticals will continue to enable medical management of select patient populations, which will increasingly shift case volumes to the outpatient setting over the next decade. This will drive growth in outpatient infusion therapy for several service lines, including rheumatology, with a 48% growth rate; gastroenterology, 37%; endocrine, 23%; and dermatology, 18%.
  • Outpatient surgical volumes to continue growing: Overall, outpatient surgical volumes are expected to grow 18% by 2033 to 109.5 million cases, led by total joint replacement, lumbar/thoracic spinal fusion and knee replacement, as volumes for these and other procedures move to lower-cost sites of care including ambulatory surgery centers, procedural offices and patient homes.
  • Care-at-home innovation drives increased utilization: Home care volume will increase 20%, driven by a culmination of advances in remote monitoring and digital health capabilities, more favorable payment and lower acuity care shifting to the home setting, enabling reduced patient length of stay and cost avoidance.
  • Virtual visits to grow: Sg2 expects 28% of 1.67 billion new and established evaluation and management (E&M) visits to occur virtually by 2033, despite payment and investment headwinds.

Sg2 annually publishes the Impact of Change Forecast, which projects demand for healthcare services across the System of CARE (clinical alignment and resource effectiveness) year over year. Learn more about the Impact of Change Forecast.

About Sg2

Sg2, a Vizient company, is the health care industry’s premier authority on health care trends, insights, and market analytics. Our analytics and expertise help hospitals and health systems achieve sustainable growth and ensure ongoing market relevance through the development of an effective System of CARE, implementation of novel payment model innovations, and consumer-driven solutions that activate patients and drive physician and customer loyalty. Learn more at www.sg2.com

About Vizient, Inc.

Vizient, Inc., the nation’s largest member-driven healthcare performance improvement company, serves more than 60% of the nation’s acute care providers, which includes 97% of the nation’s academic medical centers, and more than 25% of the non-acute care market. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $130 billion in annual purchasing volume. Vizient’s solutions and services improve the delivery of high-value care by aligning cost, quality and market performance. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.